Bristol-Myers slips after FDA gives Merck lung cancer therapy priority review

Shares of Merck are on the rise after the company announced the Food and Drug Administration has accepted for priority review its application for its immunotherapy drug Keytruda with chemotherapy as an initial treatment for advanced lung cancer.